This randomised phase II trial aimed to compare efficacy of the irreversible ErbB family blocker , afatinib , with cetuximab in patients with KRAS wild-type metastatic colorectal adenocarcinoma ( mCRC ) with progression following oxaliplatin - and irinotecan-based regimens .